Prognostic factors for failure after prostatectomy

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 1-19

  Swanson, Gregory P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Adjuvant radiation; Adjuvant therapy; High risk; Prostate cancer; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RECURRENCE; CANCER SURGERY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; GLEASON SCORE; HUMAN; LYMPH NODE; METASTASIS FREE SURVIVAL; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SEMINAL VESICLE; TREATMENT FAILURE;

EID: 84861155068     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.1     Document Type: Review

References (123)

1. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009; 181(3):956-962.
2. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366(9485): 572-578.
3. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924-30.
4. Klotz L. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention. Nat Clin Pract Urol. 2008;5:2-3.
5. Nielsen ME, Trock BJ, Walsh PC. Salvage or adjuvant radiation therapy: counseling patients on the benefits. J Natl Compr Canc Netw. 2010;8:228-37.
6. Collette L, Burzykowski T, Schröder FH. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer. 2006;42:1344-50.
7. Lofters A, Juffs HG, Pond GR, et al: "PSA-itis" knowledge of serum prostate antigen and other causes of anxiety in men with metastatic prostate cancer. J Urol 2002; 168:2516-2520
8. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59:225-49.
9. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28:1117-23.
10. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-429.
11. Tannock, IF, de Wit R, Berry WR, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med 2004 351: 1502-1512.
12. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281:1591-7.
13. Allsbrook WC, Mangold KA, Johnson MH, et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 2001. 32:74-80.
14. Steinberg DM, Sauvageot J, Piantadosi S, et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol. 1997, 21:566-76.
15. Swanson GP, Hussey MA, Tangen CM, et al. SWOG 8794.Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007; 25:2225-9.
16. Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol. 2007;25:110-4.
17. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9.
18. Eastham JA, Kelly WK, Grossfeld GD, et al. Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62:55-62.
19. McAleer SJ, Shultz D, Whittington R, et al. PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level. Urol Oncol. 2005;23:311-317.
20. Khan MA, Partin AW, Mangold LA, et al. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology. 2003; 62:866-71.
21. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169:517-23.
22. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins Experience. Urol Clin North Am 2001; 28:555-565.
23. Pierorazio PM, Epstein JI, Humphreys E, et al. The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted. J Urol. 2010;183:151-7.
24. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910-4.
25. Catalona WJ and Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998; 160: 2428-34.
26. Blute ML, Bergstralh EJ, Iocca A, et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 2001; 165:119-25.
27. Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994 Nov;152(5 Pt 2):1821-5.
28. Mian BM, Troncoso P, Okihara K, et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol, 2002; 167: 1675-80.
29. Sofer M, Savoie M, Kim SS, et al. Biochemical and pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle invasion. J Urol. 2003; 169:153-6.
30. Stephenson AJ, Wood DP, Kattan MW, et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol. 2009;182:1357-63.
31. Karakiewicz PI, Eastham JA, Graefen M, et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology. 2005;66:1245-50.
32. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002, 167:528-34.
33. Salomon L, Anastasiadis AG, Johnson CW, et al. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology 2003, 62(2):304-9.
34. D'Amico AV, Whittington R, Malkowicz SB, et al. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol. 1998;160(6 pt 1):2096-2101.
35. Quinn DI, Henshall SM, Haynes A-M, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 2001, 19:3692-3705.
36. Tefilli MV, Gheiler EL, Tiguert R, et al. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol. 1998;160(3 Pt 1): 802-6.
37. Freedland SJ, Aronson WJ, Presti JC, et al. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer 2004;100: 1633-8.
38. Tefilli MV, Gheiler EL, Tiguert R, et al. Should Gleason score 7 prostate cancer be considered a unique grade category? Urology 1999; 53: 372-377.
39. D'Amico AV, Whittington R, Malkowicz SB, et al. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol. 2000; 18:3240-6.
40. Swanson GP, Goldman B, Tangen CM, et al. Southwest Oncology Group 8794.The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol. 2008; 180:2453-7.
41. Oefelein MG., Smith ND., Grayhack JT, et al. Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol. 1997; 158: 1460-5.
42. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol. 1990; 144:1180-4.
43. Frazier HA, Robertson JE, Humphrey PA, et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol. 1993; 149:516-8.
44. Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy: a multi-variate analysis of 721 men with long term follow-up. Am J Surg Pathol 1996; 20: 286-292.
45. Ohori M., Goad JR., Wheeler TM, et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994; 152: 1843-9.
46. Lau WK, Bergstralh EJ, Blute ML, et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002; 167:117-22.
47. Rodriguez-Covarrubias F, Larre S, De La Taille A, et al. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy. BJU Int. 2008; 101:305-7.
48. Grossfeld GD, Latini DM, Lubeck DP, et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003; 169:157-63.
49. Kupelian PA, Katcher J, Levin HS, et al. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys. 1997; 37:1043-52.
50. Sakr WA, Tefilli MV, Grignon DJ, et al. Gleason score 7 prostate cancer: A heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 2000; 56:730-734.
51. Chan TY, Partin AW, Walsh PC, et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000; 56:823-827.
52. Lau WK, Blute ML, Bostwick DG, et al. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: Differences in outcome between primary Gleason grades 3 and 4. J Urol 2001; 166:1692-1697.
53. Wheeler TM, Dillioglugil O, Kattan MW, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 1998, 29:856-862.
54. San Francisco IF, Regan MM, Olumi AF, et al. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. J Urol. 2004; 171:1492-9.
55. Stamey TA, Yemoto CM, McNeal JE, et al. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol. 2000; 163:1155-60.
56. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125-35.
57. Freedland SJ, Dorey F, Aronson WJ. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 2001;57:476-80.
58. Loeb S, Kan D, Yu X, et al. Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy. J Urol. 2010; 183:1816-21.
59. Gonzalez CM, Roehl KA, Antenor JV, et al. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. Urology. 2004; 64:723-8.
60. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150:110-4.
61. Epstein JI. Pathologic assessment of the surgical specimen. Urol Clin North Am. 2001; 28:567-94.
62. Theiss M, Wirth MP, Manseck A, et al. Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy. Prostate 1995, 27:13-17.
63. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol. 1994; 152(5 Pt 2):1826-30.
64. Pfitzenmaier J, Pahernik S, Tremmel T et al. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression? BJU Int 2008; 102: 1413.
65. Cheng L, Darson MF, Bergstralh EJ, et al. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 1999; 86: 1775-82.
66. Simon MA, Kim S, Soloway MS. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol. 2006; 175:140-4.
67. Pettus JA, Weight CJ, Thompson CJ, et al. Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol. 2004; 172:129-32.
68. Vis AN, Roemeling S, Kranse R, et al. Should we replace the Gleason score with the amount of high-grade prostate cancer? Eur Urol. 2007; 51:931-9.
69. Jayachandran J, Bañez LL, Levy DE, et al. SEARCH Database Study Group. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol. 2008; 179:1791-6.
70. Mann MJ, DeCastro GJ, Desai M, et al. Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era. Urology. 2008; 72:1203-7.
71. Kupelian P, Katcher J, Levin H, et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profilesafter radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48: 249-60.
72. Quinn DI, Henshall SM, Brenner PC, et al. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer 2003; 97: 1884-1893.
73. D'Amico AV, Whittington R, Malkowicz SB, et al. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7. Cancer 2000; 88:2110-5.
74. van den Ouden D., Bentvelsen FM., Boeve ER, et al. Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Brit. J Urol. 1993; 72: 489-94.
75. Alkhateeb S, Alibhai S, Fleshner N, et al. Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol. 2010;183:145-50.
76. Epstein JI, Carmichael MJ, Pizov G, et al. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 1993, 150:135-141.
77. Lowe BA, and Lieberman SF, Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 1997;158: 1452-1456.
78. Obek C, Sadek S, Lai S, et al. Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology. 1999; 54:682-8.
79. Freedland SJ, Presti JC, Kane CJ, et al. Do younger men have better biochemical outcomes after radical prostatectomy? Urology 2004, 63(3):518-22.
80. Smith CV, Bauer JJ, Connelly RR, et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol 2000; 164: 1964-1967.
81. Khan MA, Han M, Partin AW, et al. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 2003; 62: 86-91.
82. Siddiqui SA, Sengupta S, Slezak JM, et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol 2006; 175: 952-7.
83. Magheli A, Rais-Bahrami S, Humphreys EB, et al. Impact of patient age on biochemical recurrence rates following radical prostatectomy. J Urol. 2007; 178:1933-7.
84. Gretzer MB, Epstein JI, Pound CR, et al. Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology. 2002; 60:1034-9
85. Amling CL, Riffengurgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 439-45.
86. Eastham JA, and Kattan MW. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol 2000; 163: 143-145.
87. Fowler JE, and Terrell F. Survival in blacks and whites after treatment for localized prostate cancer. J Urol 1996; 156: 133-136.
88. Iselin CE, Box JW, Vollmer RT, et al. Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer 1998; 83: 2353-2360.
89. Endrizzi J, Seay T. The relationship between early biochemical failure and perineural invasion in pathological T2 prostate cancer. Br J Urol 2000; 85:696.
90. Epstein JI. The role of perineural invasion and other bio -characteristics as prognostic markers for localized prostate cancer. Sem Urol Oncol. 1998; 16:124.
91. dela Taille A, Rubin MA, Bagiella E, et al. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy? J Urol. 1999; 162:103-6.
92. Grignon DJ, Sakr WA. Pathologic staging of prostate carcinoma. What are the issues? Cancer 1996; 78:337-40.
93. Epstein JI, Carmichael M, Partin AW, et al. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol. 1993; 149:1478-8.
94. Kikuchi E, Scardino PT, Wheeler TM, et al. Is tumour volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004, 172:508-11.
95. Ramos CG, Roehl KA, Antenor JA, et al. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol. 2004; 172:137-40.
96. Freedland SJ, Wieder JA, Jack GS, et al. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol. 2002; 168:110-5.
97. Schroeck FR, Kattan MW, Moul JW, et al. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU Int. 2009;[Epub ahead of print]
98. Freedland SJ, Csathy GS, Frederick D, et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002; 167: 516-520.
99. Cupp MR, Bostwick PG, Myers RP, et al. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995; 153: 1543-8.
100. Freedland SJ, Aronson WJ, Terris MK, et al. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2003; 98:2344-50.
101. Linson PW, Lee AK, Doytchinova T, et al. Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific antigen outcome for men with intermediate-risk prostate cancer? Urology. 2002; 59:704-8.
102. Grossfeld GD, Latini DM, Lubeck DP, et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology. 2002; 59: 560-5.
103. Presti JC Jr, Shinohara K, Bacchetti P, et al. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology. 1998; 52:1079-84.
104. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124:995-1000.
105. Strohmeyer D, Rossing C, Strauss F, et al.: Tumour angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000, 42:26-33.
106. van den Ouden D, Hop WC, Kranse R, et al. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol. 1997; 79:203-11.
107. Silberman MA, Partin AW, Veltri RW, et al: Tumor angiogenesis correlates with progression after radical prostatectomy butnot with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79: 772-779.
108. Rubin MA, Buyyounouski M, Bagiella E, et al.: Microvessel density in prostate cancer: lack of correlation with tumour grade, pathologic stage, and clinical outcome. Urology 1999, 53:542-547.
109. Gettman MT, Pacelli A, Slezak J, et al.: Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology 1999, 54:479-485.
110. Bettencourt MC, Bauer JJ, Sesterhenn A, et al. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998; 160:459-465.
111. Gettman MT, Bergstralh EJ, Blute M, et al: Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology 1998; 51: 79-85.
112. Lee SE, Currin SM, Paulson DF, et al. Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J Urol. 1988; 140:769-74.
113. Montgomery BT, Nativ O, Blute ML, et al. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg. 1990; 125:327-31.
114. Nativ O, Winkler HZ, Raz Y, et al. Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. Mayo Clin Proc. 1989; 64:911-9.
115. Hawkins CA, Bergstralh EJ, Lieber MM, et al. Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy. Urology. 1995; 46:356-64.
116. Carmichael MJ, Veltri RW, Partin AW, et al. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol. 1995; 153(3 Pt 2):1015-9.
117. Halvorsen OJ, Hostmark J, Haukaas S, et al. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 2000, 88: 416-424.
118. D'Amico, A. V., Whittington, R., Malkowicz, S. B., et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280: 969-74.
119. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005; 23:7005-12.
120. Kattan MW, Vickers AJ, Yu C, et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer. 2009;115:1005-10.
121. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17:1499-507
122. Walz J, Chun FK, Klein EA, et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol. 2009; 181:601-7.
123. Moinpour CM, Hayden KA, Unger JM, et al. Health related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 2008; 26: 112.